Qiu, H., Guo, R. (2026). Penpulimab plus anlotinib as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A multicentre, single-arm, phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.211